HCV Frenzy Continues: Novartis Licenses Enanta NS5A Inhibitor
Continuing the recent frenzy of dealmaking activity in the hepatitis C virus (HCV) space, Enanta Pharmaceuticals Inc. is expected to announce Tuesday morning that it licensed preclinical NS5A inhibitor EDP-239 to Novartis AG in a deal worth up to $440 million.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST